AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15583914 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT measurements of DAT and D2 receptor binding
Number of subjects: 33
Study 11323374 — intervention group
Group type: COMPARATOR
Intervention: Awake fiberoptic intubation (AFOI)
Number of subjects: 38
Study 11323374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA)
Number of subjects: 38
Study 9211474 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg proglumide
Number of subjects: 0
Study 9211474 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg proglumide
Number of subjects: 0
Study 9211474 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg proglumide
Number of subjects: 0
Study 9211474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 0
Study 9211474 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 0
Study 7949999 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 200
Study 7949999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHESS)
Number of subjects: 200
Study 2970220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 physicians received individualized decision analysis; 39% took actions recommended (screening or vaccination).
Number of subjects: 1280
Study 2970220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 physicians received general information about vaccine decisions; specific outcome not detailed.
Number of subjects: 1280
Study 2970220 — intervention group
Group type: COMPARATOR
Intervention: Group 3 physicians served as controls; specific outcome not detailed.
Number of subjects: 1280
Study 31736335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4443
Study 31736335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4443
Study 30017645 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 850
Study 30017645 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 850
Study 28699558 — intervention group
Group type: EXPERIMENTAL
Intervention: Temephos exposure
Number of subjects: 0
Study 28699558 — intervention group
Group type: COMPARATOR
Intervention: Control (no temephos exposure)
Number of subjects: 0
Study 25964628 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma XC
Number of subjects: 235
Study 24138062 — intervention group
Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 142
Study 24138062 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 142
Study 24138062 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the dural sac
Number of subjects: 142
Study 16598087 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA through the medial parapatellar approach
Number of subjects: 70
Study 16598087 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation TKA
Number of subjects: 70
Study 16598087 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA through the subvastus approach
Number of subjects: 70
Study 14714360 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshao Granule (DSG)
Number of subjects: 63
Study 14714360 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium polyglycosides tablet and composite Salviae tablet (Control)
Number of subjects: 63
Study 9927122 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60
Study 9927122 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study 7561157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6% all‐trans‐retinol (ROL)
Number of subjects: 10
Study 7561157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% all‐trans‐retinoic acid (RA)
Number of subjects: 10
Study 7561157 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (70% ethanol/30% propylene glycol)
Number of subjects: 10
Study 2048660 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Number of subjects: 20
Study 2048660 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Number of subjects: 20
Study 7272153 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg
Number of subjects: 9
Study 7272153 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.3 mg or 0.2 mg
Number of subjects: 9
Study 29496604 — intervention group
Group type: EXPERIMENTAL
Intervention: Star labels
Number of subjects: 306
Study 29496604 — intervention group
Group type: COMPARATOR
Intervention: Traffic light labels
Number of subjects: 306
Study 29496604 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of framing (gain, loss, gain + loss)
Number of subjects: 306
Study 29496604 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing information
Number of subjects: 306
Study 29496604 — intervention group
Group type: EXPERIMENTAL
Intervention: Label type (star vs. traffic light)
Number of subjects: 306
Study 28573190 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 80
Study 28573190 — intervention group
Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 80
Study 25774660 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-mentoring intervention
Number of subjects: 182
Study 24040847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg b.i.d. for 6 days prior to inhalation of glycopyrronium
Number of subjects: 20
Study 24040847 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 100 μg inhaled alone
Number of subjects: 20
Study 21156335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) plus Bacillus Calmette-Guérin (BCG)
Number of subjects: 96
Study 21156335 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG) alone
Number of subjects: 96
Study 18453021 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 26
Study 18453021 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 26
Study 15681941 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ml saline injection
Number of subjects: 28
Study 15681941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ml saline injection
Number of subjects: 28
Study 15681941 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-ml saline injection
Number of subjects: 28
Study 15681941 — intervention group
Group type: COMPARATOR
Intervention: Control (no saline injection)
Number of subjects: 28
Study 12851515 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI+ (Isoflavone-rich soy protein isolate)
Number of subjects: 69
Study 12851515 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI- (Isoflavone-poor soy)
Number of subjects: 69
Study 12851515 — intervention group
Group type: COMPARATOR
Intervention: Whey control
Number of subjects: 69
Study 10098816 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment (VE) immersion for 20 minutes
Number of subjects: 0
Study 10098816 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturographic technique
Number of subjects: 0
Study 10098816 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator sickness symptoms
Number of subjects: 0
Study 15374159 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 7 days
Number of subjects: 29
Study 15374159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15374159 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 29
Study 1817630 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pretreatment with pancuronium (100 micrograms kg‐1)
Number of subjects: 2
Study 1817630 — intervention group
Group type: COMPARATOR
Intervention: Priming dose of pancuronium (10 micrograms kg‐1)
Number of subjects: 2
Study 6127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (1 mg/kg i.v. during the first 2 days followed by a daily oral dose of 600 mg for 3 weeks)
Number of subjects: 26
Study 6127172 — intervention group
Group type: COMPARATOR
Intervention: Control (12 untreated subjects)
Number of subjects: 26
Study 6127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 26
Study 6127172 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 31145174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 24 weeks)
Number of subjects: 64
Study 31145174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 64
Study 31145174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30639666 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality enhanced bullying prevention program
Number of subjects: 118
Study 30639666 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 118
Study 28385440 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained fixed metal-acrylic resin prostheses
Number of subjects: 22
Study 28385440 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures
Number of subjects: 22
Study 26103191 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Plan
Number of subjects: 10
Study 26103191 — intervention group
Group type: COMPARATOR
Intervention: Clinical Plan
Number of subjects: 10
Study 26103191 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF Plan
Number of subjects: 10
Study 24428951 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex breastfeeding support intervention (prenatal/postnatal professional and peer support package continuing till 6 months postpartum)
Number of subjects: 443
Study 24428951 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex breastfeeding support intervention
Number of subjects: 443
Study 24428951 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal and postnatal care (Control)
Number of subjects: 443
Study 22948223 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dietary weight loss
Number of subjects: 83
Study 19447479 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Number of subjects: 296
Study 19447479 — intervention group
Group type: COMPARATOR
Intervention: 3 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Number of subjects: 296
Study 17293705 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 24
Study 17293705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15057546 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 45
Study 12368388 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable diet
Number of subjects: 37
Study 9650870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy plus scaling (group 2)
Number of subjects: 16
Study 9650870 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (group 1)
Number of subjects: 16
Study 9650870 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy plus scaling (group 4)
Number of subjects: 16
Study 9650870 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy but no scaling (group 3)
Number of subjects: 16
Study 9650870 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of metronidazole plus amoxicillin
Number of subjects: 16
Study 7639570 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 MU intravesical alpha‐2b interferon (IFN)
Number of subjects: 60
Study 7639570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study 2651328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.4 mg) and atenolol (100 mg)
Number of subjects: 17
Study 2651328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) and nifedipine (20 mg)
Number of subjects: 17
Study 2651328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) and nicardipine (40 mg)
Number of subjects: 17
Study 2651328 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg) alone
Number of subjects: 17
Study 2651328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2651328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.4 mg)
Number of subjects: 17
Study 406634 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (up to 10 mg)
Number of subjects: 0
Study 31557537 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Step Test (IST)
Number of subjects: 20
Study 31557537 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary Exercise Testing (CPET)
Number of subjects: 20
Study 31418258 — intervention group
Group type: EXPERIMENTAL
Intervention: fT4 levels
Number of subjects: 49
Study 31418258 — intervention group
Group type: EXPERIMENTAL
Intervention: fT3 levels
Number of subjects: 49
Study 31418258 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels
Number of subjects: 49
Study 28222556 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with a mass attached on non-paretic lower limb (NPLL)
Number of subjects: 38
Study 28222556 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training only (control group)
Number of subjects: 38
Study 28222556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 38
Study 25939655 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (HS; wearing firefighter personal protective equipment (PPE))
Number of subjects: 12
Study 25939655 — intervention group
Group type: COMPARATOR
Intervention: No heat stress (NHS; wearing a cooling shirt and equivalent PPE weight)
Number of subjects: 12
Study 23650429 — intervention group
Group type: EXPERIMENTAL
Intervention: Unselected young TILs
Number of subjects: 69
Study 23650429 — intervention group
Group type: COMPARATOR
Intervention: CD8(+)-enriched TILs
Number of subjects: 69
Study 21439302 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure using a neodymium-iron-boron magnet, 30-minute exposure interval
Number of subjects: 18
Study 21439302 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control group)
Number of subjects: 18
Study 18931006 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide ER (8 mg/day for 4 weeks, 16 mg/day for 6 weeks, 24 mg/day for 6 weeks)
Number of subjects: 69
Study 18931006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 16514250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cytology
Number of subjects: 22
Study 16514250 — intervention group
Group type: COMPARATOR
Intervention: Histological examination of permanent sections
Number of subjects: 22
Study 15485290 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-dose WHO multi-drug therapy (Group 1, 128 patients)
Number of subjects: 213
Study 15485290 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-dose WHO multi-drug therapy (Group 2, 85 patients)
Number of subjects: 213
Study 10932574 — intervention group
Group type: EXPERIMENTAL
Intervention: Public feedback
Number of subjects: 108
Study 10932574 — intervention group
Group type: EXPERIMENTAL
Intervention: Private feedback
Number of subjects: 108
Study 10932574 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study 9174308 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) using propofol with a basal infusion of propofol, n = 20
Number of subjects: 37
Study 9174308 — intervention group
Group type: COMPARATOR
Intervention: Neurolept analgesia using an initial bolus dose of fentanyl and droperidol followed by a fentanyl infusion, n = 17
Number of subjects: 37
Study 1542321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140
Study 1542321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 4020569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid oral rehydration using ORS‐WHO (sodium 90 mmol/L)
Number of subjects: 81
Study 4020569 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral fluid replacement (sodium 35 mmol/L)
Number of subjects: 81
Study 4020569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid return to full feedings appropriate for age
Number of subjects: 81
Study 4020569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g four times daily
Number of subjects: 81
Study 4020569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine in children with poor initial hydration
Number of subjects: 81
Study 31294581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desks
Number of subjects: 127
Study 31294581 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 29672519 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect labelling condition
Number of subjects: 110
Study 29672519 — intervention group
Group type: COMPARATOR
Intervention: Non-affect labelling condition (control)
Number of subjects: 110
Study 26874387 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP), 10 μg/kg, administered subcutaneously twice daily for 12 weeks
Number of subjects: 36
Study 26874387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25253884 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 16
Study 25253884 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 25253884 — intervention group
Group type: EXPERIMENTAL
Intervention: 6',7'-dihydroxybergamottin (DHB)
Number of subjects: 16
Study 25253884 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIVE approach
Number of subjects: 16
Study 25253884 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous GFJ-drug interaction studies
Number of subjects: 16
Study 23115989 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical physical therapy group (ultrashort wave and magnetic therapy instrument, once a day, 5 days for a course of treatment, three cycles)
Number of subjects: 90
Study 23115989 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine group (beta-aescin 20 mg IV once a day for 5 days, followed by Danshen injection 20 ml IV once a day for 10 days)
Number of subjects: 90
Study 23115989 — intervention group
Group type: COMPARATOR
Intervention: Control group (raised and exercised limb and fingers only)
Number of subjects: 90
Study 20595697 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupoint (Liv3)
Number of subjects: 10
Study 20595697 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 10
Study 18552399 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 90
Study 18552399 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 90
Study 18552399 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A4 STin2 12/12 carriers
Number of subjects: 90
Study 15624054 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group using the laparoscopic camera navigation simulator
Number of subjects: 20
Study 15624054 — intervention group
Group type: COMPARATOR
Intervention: Control group with no training
Number of subjects: 20
Study 12400198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing staff directly asking questions about domestic violence during initial assessment
Number of subjects: 0
Study 12400198 — intervention group
Group type: COMPARATOR
Intervention: Stimulus (button) worn by nursing staff in the emergency department
Number of subjects: 0
Study 10529509 — intervention group
Group type: EXPERIMENTAL
Intervention: wt1 gene expression in newly diagnosed leukemias
Number of subjects: 61
Study 10529509 — intervention group
Group type: EXPERIMENTAL
Intervention: wt1 gene expression in relapsed leukemias
Number of subjects: 61
Study 10529509 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of wt1 expression levels
Number of subjects: 61
Study 10529509 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of wt1 expression in acute childhood leukemias
Number of subjects: 61
Study 7818005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol 300 mg
Number of subjects: 233
Study 7818005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol 600 mg
Number of subjects: 233
Study 7818005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol 1200 mg
Number of subjects: 233
Study 7818005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 2150695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 20
Study 2150695 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 20
Study 2150695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 20
Study 111759 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 1 unit/ml of infusate
Number of subjects: 80
Study 111759 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 80
Study 6130075 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 6130075 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 31429974 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week smartphone-based aftercare intervention (German version of 'Recovery Record') with therapist feedback as an adjunct to treatment as usual
Number of subjects: 40
Study 31429974 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week smartphone-based aftercare intervention
Number of subjects: 40
Study 31429974 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 40
Study 29996843 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA) 2.4 g/d for 28 days
Number of subjects: 12
Study 29996843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 29996843 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA)
Number of subjects: 12
Study 26873040 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable long ITI (mean=57 s, range 25-123 s)
Number of subjects: 0